RESUMO
This study aimed to explore the value of magnetic resonance imaging (MRI) T2 mapping in the assessment of dermatomyositis (DM) and polymyositis (PM). Thirty-three confirmed cases (myosin group) and eight healthy volunteers (healthy control group) at the Department of Rheumatology and Immunology, the First Affiliated Hospital of Kunming Medical University, from October 2016 to December 2017, were collected and analyzed. Multiple parameters of the myosin group were quantified, including creatine kinase (CK), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement C3, and complement C4. Disease status was evaluated using a panel of tools: myositis disease activity assessment tool-muscle (MDAAT-muscle), myositis disease activity assessment tool-whole (MDAAT-all), health assessment questionnaire (HAQ), medical outcomes study health survey short form-36 item (SF-36), hand muscle strength test (MMT-8) score, and MRI T2 mapping of muscle (22 muscles in the pelvis and thighs) T2 values. The results showed that in the myositis group, the measurements for CK, ESR, CRP, complement C3, and complement C4 were 457.2 (165.6, 1 229.2) IU/L, 20 (10, 42) mm/1h, 3.25 (2.38, 10.07) mg/L, 0.90 (0.83, 1.06) g/L, and 0.18 (0.14, 0.23) g/L, respectively. The scores for MMT-8, MDAAT-muscle, MDAAT-all, HAQ, and SF-36 were 57.12±16.23, 5.34 (4.00, 6.00), 34.63±12.62, 1.55 (0.66, 2.59), and 44.66±7.98, respectively. T2 values were significantly higher in all 22 muscles of the pelvis and thighs of patients with DM or PM compared with the healthy controls [(54.99±11.60)ms vs. (36.62±1.66)ms, P<0.001], with the most severe lesions in the satrorius, iliopsoas, piriformis, gluteus minimus, and gluteus medius muscles. The total muscle T2 value in the myositis group was positively correlated with CK, MDAAT-muscle, MDAAT-all, and HAQ (r=0.461, 0.506, 0.347, and 0.510, respectively, all P<0.05). There was a negative correlation between complement C4, SF-36, and MMT-8 scores (r=-0.424, -0.549, and -0.686, respectively, all P<0.05). Collectively, the findings from this study suggest that MRI T2 mapping can objectively reflect the disease status of DM and PM.
Assuntos
Dermatomiosite , Miosite , Polimiosite , Humanos , Dermatomiosite/diagnóstico por imagem , Complemento C3 , Polimiosite/diagnóstico por imagem , Polimiosite/patologia , Miosite/patologia , Proteína C-Reativa/metabolismo , Imageamento por Ressonância Magnética/métodos , Creatina Quinase , Complemento C4 , MiosinasRESUMO
INTRODUCTION/AIMS: Muscle strength, functional status, and muscle enzymes are conventionally used to evaluate disease status in idiopathic inflammatory myopathies (IIM). This study aims to investigate the role of quantitative muscle ultrasound in evaluating disease status in IIM patients. METHODS: Patients with IIM, excluding inclusion body myositis, were recruited along with age- and sex-matched healthy controls (HC). All participants underwent muscle ultrasound and clinical assessments. Six limb muscles were unilaterally scanned using a standardized protocol, measuring muscle thickness (MT) and echo intensity (EI). Results were compared with HC, and correlations were made with outcome measures. RESULTS: Twenty IIM patients and 24 HC were recruited. The subtypes of IIM were dermatomyositis (6), necrotizing myositis (6), polymyositis (3), antisynthetase syndrome (3), and nonspecific myositis (2). Mean disease duration was 8.7 ± 6.9 years. There were no significant differences in demographics and anthropometrics between patients and controls. MT of rectus femoris in IIM patients was significantly lower than HC. Muscle EI of biceps brachii and vastus medialis in IIM patients were higher than HC. There were moderate correlations between MT of rectus femoris and modified Rankin Scale, Physician Global Activity Assessment, and Health Assessment Questionnaire, as well as between EI of biceps brachii and Manual Muscle Testing-8. DISCUSSION: Muscle ultrasound can detect proximal muscle atrophy and hyperechogenicity in patients with IIM. The findings correlate with clinical outcome measures, making it a potential tool for evaluating disease activity of patients with IIM in the late phase of the disease.
Assuntos
Miosite de Corpos de Inclusão , Miosite , Polimiosite , Humanos , Miosite/complicações , Miosite/diagnóstico por imagem , Músculo Esquelético , Polimiosite/patologia , Miosite de Corpos de Inclusão/patologia , Atrofia Muscular/patologiaRESUMO
OBJECTIVE: Inflammatory myopathies (IIM) include dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and overlap myositis (OLM)/antisynthetase syndrome (ASyS). There is also a rare variant termed polymyositis with mitochondrial pathology (PM-Mito), which is considered a sIBM precursor. There is no information regarding muscle MRI for this rare entity. The aim of this study was to compare MRI findings in IIM, including PM-Mito. METHODS: This retrospective analysis included 41 patients (7 PM-Mito, 11 sIBM, 11 PM/ASyS/OLM, 12 IMNM) and 20 healthy controls. Pattern of muscle involvement was assessed by semiquantitative evaluation, while Dixon method was used to quantify muscular fat fraction. RESULTS: The sIBM typical pattern affecting the lower extremities was not found in the majority of PM-Mito-patients. Intramuscular edema in sIBM and PM-Mito was limited to the lower extremities, whereas IMNM and PM/ASyS/OLM showed additional edema in the trunk. Quantitative assessment showed increased fat content in sIBM, with an intramuscular proximo-distal gradient. Similar changes were also found in a few PM-Mito- and PM/ASyS/OLM patients. In sIBM and PM-Mito, mean fat fraction of several muscles correlated with clinical involvement. INTERPRETATION: As MRI findings in patients with PM-Mito relevantly differed from sIBM, the attribution of PM-Mito as sIBM precursor should be critically discussed. Some patients in PM/ASyS/OLM and PM-Mito group showed MR-morphologic features predominantly observed in sIBM, indicative of a spectrum from PM/ASyS/OLM toward sIBM. In some IIM subtypes, MRI may serve as a biomarker of disease severity.
Assuntos
Imageamento por Ressonância Magnética , Músculo Esquelético , Miosite , Polimiosite , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Estudos Retrospectivos , Miosite/diagnóstico por imagem , Miosite/patologia , Polimiosite/diagnóstico por imagem , Polimiosite/patologia , Músculo Esquelético/diagnóstico por imagem , Músculo Esquelético/patologia , Adulto , Idoso , Imagem Corporal Total/métodosRESUMO
INTRODUCTION/AIMS: Myxovirus resistance protein A (MxA) is a type I interferon (IFN1) pathway activation marker and MxA sarcoplasmic expression is currently recognized as a highly specific marker for dermatomyositis (DM). However, we have frequently observed endothelial tubuloreticular inclusions (TRI), another surrogate IFN1 activation marker, in a variety of overlap myositides. The aim of this study was to examine MxA expression in those myositides. METHODS: We retrospectively performed MxA immunostaining on a wide range of myositides. RESULTS: MxA sarcoplasmic expression was present in DM (94.4%, 17/18), active lupus myositis (LM, 80%,16/20), inactive LM (36%, 4/11), antisynthetase syndrome (ASyS, 20%, 2/10), systemic sclerosis (13%, 2/15), Sjogren's syndrome (7.7%, 1/13), and human immunodeficiency virus (HIV) myositis (5.6%, 1/18) and was absent in immune-mediated necrotizing myopathy (IMNM, 0/16) and hydroxychloroquine myopathy (0/5). The sensitivity and specificity of MxA sarcoplasmic expression for LM and DM combined compared with all other myositides were 84.6% (95% CI: 69.5-94.1) and 92.1 (95% CI: 83.6-97.0), respectively, and superior to TRIs. MxA capillary expression was nonspecific. Histologically, 35% of LM cases demonstrated a unique panfascicular necrotizing myopathy pattern. The remainder of the LM cases had significant morphological overlap with DM/ASyS (20%), IMNM (20%), or polymyositis (15%). DISCUSSION: MxA sarcoplasmic expression is highly prevalent in LM and DM and is a useful marker in differentiating DM and LM from other myositides. LM can manifest in various pathology patterns that need to be differentiated from DM, IMNM, ASyS, and polymyositis.
Assuntos
Dermatomiosite , Doenças Musculares , Miosite , Orthomyxoviridae , Polimiosite , Humanos , Biomarcadores , Dermatomiosite/patologia , Miosite/patologia , Polimiosite/patologia , Estudos RetrospectivosRESUMO
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes, myopathic changes on electromyography and an abnormal muscle biopsy. The different IIM have been classified according to their distinctive histopathologic features in dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and immune-mediated necrotizing myopathy (IMNM). Several myositis-specific antibodies are associated with the different phenotypes, as well as with different risk of neoplastic disease and systemic complications. The basis for the treatment of DM, PM, and IMNM is immunosuppression. For IBM there are only symptomatic treatments. Steroids, associated or not with other immunosuppressant drugs, are the first line of treatment. Biologic drugs will allow future individualized therapies. The 10-year survival of DM, PM and IMNM is 62 to 90%. The leading causes of death are neoplastic, lung and cardiac complications. IBM does not impair survival, although it affects the quality of life.
Assuntos
Humanos , Miosite/patologia , Polimiosite/patologia , Músculo Esquelético/patologia , Dermatomiosite/patologia , Eletromiografia , Imunossupressores/classificação , Imunossupressores/uso terapêutico , Anticorpos , Miosite/tratamento farmacológicoRESUMO
La mayoría de los estudios de tratamiento de las miopatías inflamatorias son de corte y no permiten establecer su eficacia en largo plazo. En este trabajo, describimos el seguimiento de siete pacientes con miopatías inflamatorias, 5 polimiositis y 2 dermatomiositis. Determinamos su presentación, su seguimiento clínico mediante el examen físico, las enzimas musculares y la respuesta al tratamiento. Esta última la definimos como cursos de tratamiento, donde cada curso termina al aumentar los corticoides o al colocar una nueva medicación inmunosupresora debido al empeoramiento clínico o aumento sostenido de las enzimas musculares. El tratamiento instaurado puede remitir, controlar parcialmente, o fracasar en controlar la enfermedad en cuanto se normalicen, estabilicen, o no modifiquen respectivamente tanto la clínica como las enzimas musculares. Se analizaron 20 ciclos, en 14 se logró la remisión, en cinco se controló parcialmente y en uno fracasó el tratamiento. La remisión se logró en un tiempo promedio de 139 ± 98 días y el control en un promedio de 160 ± 100 días. Excepto en una ocasión, todos los ciclos de tratamiento, independientemente del que fuera, remitieron o controlaron los síntomas, pero en el tiempo todos los pacientes recidivaron en su enfermedad.
Most studies about treatment of inflammatory myopathies consist of cross-sectional analyses that do not assess long-term efficacy. In the present study we describe the follow-up of seven patients with inflammatory myopathies, 5 polymyositis and 2 dermatomyositis. We describe their clinical features, follow-up, muscle enzyme levels, and treatment responses. We define the latter as treatment cycles, every one of which end when steroid doses need to be increased or a new immunosuppressive drug has to be added because of clinical worsening or sustained increases in muscle enzyme levels. Treatment can cause remission, partially control, or fail in achieving myositis improvement when it normalizes, stabilizes, or does not affect muscle enzymes or clinical features, respectively. We analyzed 20 cycles, in which remission was achieved in 14 cases, partial control in 5 instances, and treatment failure in one case. Remission occurred after an average of 139 ± 98 days, whereas partial control took place in 160 ± 100 days. Except in one case, all treatment cycles controlled or remitted the symptoms. However, in all patients the illness recurred with time.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Polimiosite/patologia , Polimiosite/tratamento farmacológico , Dermatomiosite/patologia , Dermatomiosite/tratamento farmacológico , Recidiva , Fatores de Tempo , Seguimentos , Resultado do Tratamento , Polimiosite/enzimologia , Corticosteroides/uso terapêutico , Dermatomiosite/enzimologia , Imunossupressores/uso terapêuticoRESUMO
Polymyositis (PM) is an autoimmune disease characterized by chronic inflammation in skeletal muscle. Mean platelet volume (MPV), a marker in the assessment of systemic inflammation, is easily measured by automatic blood count equipment. However, to our knowledge, there are no data in the literature with respect to MPV levels in PM patients. Therefore, in this study we aimed to investigate MPV levels in patients with PM. This study included 92 newly diagnosed PM patients and 100 healthy individuals. MPV levels were found to be significantly lower compared with healthy controls (10.3±1.23 vs 11.5±0.74 fL, P<0.001). Interestingly, MPV was found to be positively correlated with manual muscle test (MMT) score and negatively correlated with erythrocyte sedimentation rate (ESR) in patients with PM (r=0.239, P=0.022; r=−0.268, P=0.010, respectively). In addition, MPV was significantly lower in active PM patients compared with inactive PM patients (9.9±1.39 vs 10.6±0.92 fL, P=0.010). MPV was independently associated with PM in multivariate regression analyses, when controlling for hemoglobin and ESR (OR=0.312, P=0.031, 95%CI=0.108 to 0.899). The ROC curve analysis for MPV in estimating PM patients resulted in an area under the curve of 0.800, with sensitivity of 75.0% and specificity of 67.4%. Our results suggest that MPV is inversely correlated with disease activity in patients with PM. MPV might be a useful tool for rapid assessment of disease severity in PM patients.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Volume Plaquetário Médio/métodos , Polimiosite/sangue , Polimiosite/patologia , Biomarcadores/sangue , Sedimentação Sanguínea , Proteína C-Reativa/análise , Estudos de Casos e Controles , Contagem de Linfócitos , Análise Multivariada , Neutrófilos , Valores de Referência , Estudos Retrospectivos , Sensibilidade e Especificidade , Índice de Gravidade de DoençaAssuntos
Humanos , Infecções por Deltaretrovirus/complicações , Medicina Tropical , Paraparesia Espástica Tropical/diagnóstico , Polimiosite/diagnóstico , Vírus Linfotrópico T Tipo 1 Humano , Diagnóstico Diferencial , Jamaica , Paraparesia Espástica Tropical/etiologia , Paraparesia Espástica Tropical/patologia , Polimiosite/etiologia , Polimiosite/patologiaRESUMO
We describe a 41 years old woman who 17 years ago presented hypotonia and proximal muscular weakness in the upper and lower limbs. On neurological examination, the biceps, triceps and Achilles reflexes were absent; the brachioradialis reflexes were decreased and the patellar reflexes were normal. There was bilateral Babinski sign. The remainder of the neurological examination was unremarkable. In the investigation a myopathic pattern was found in the electromyography. The nerve-conduction study was normal; a ELISA method for HTLV-I antibodies was positive in the blood and in the cerebral spinal fluid. The muscle biopsy showed inflammatory myopathy, compatible with polymyositis. This paper focuses the polymyositis in the beginning of an HTLV-I infection case
Assuntos
Humanos , Feminino , Adulto , Infecções por HTLV-I/complicações , Polimiosite/virologia , Biópsia , Eletromiografia , Ensaio de Imunoadsorção Enzimática , Anticorpos Anti-HTLV-I/sangue , Anticorpos Anti-HTLV-I/líquido cefalorraquidiano , Infecções por HTLV-I/patologia , Polimiosite/patologiaRESUMO
Patients with dermatomyositis (DM) or polymyositis (PM) were studied retrospectively. The patients were divided into four groups: definite PM 24, probable PM 19, definite DM 34 and mild-early DM 25 cases. PM patients complained more often proximal muscle weakness [p <0.01]. DM patients complained more arthralgia [p <0.05], dysphagia [p <0.03] and weight loss [p <0.04]. Five patients had a malignant neoplasm and 9 had other connective-tissue disease. DM presented higher ESR than PM [p <0.002]. PM presented more significant increase in creatine kinase (CK) [p <0.02] and in alanine aminotransferase (ALT) [p <0.001] levels. Electromyography showed myopathic pattern in 76 percent. Muscle biopsy was the definitive test. Perifascicular atrophy was more frequent in definite DM than in mild-early DM group [p <0.03]. CONCLUSION: A small association with connective-tissue diseases and neoplasms was found. DM and PM are clinically different. DM presents systemic involvement affecting the skin, developing more severe arthralgia, dysphagia and weight loss and presenting higher values of ESR. PM presents a restricted and more significant involvement of muscles generating more weakness complaints and higher levels of serum muscle enzymes
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Dermatomiosite/patologia , Polimiosite/patologia , Idoso de 80 Anos ou mais , Alanina Transaminase/sangue , Biópsia , Sedimentação Sanguínea , Creatina Quinase/sangue , Dermatomiosite/complicações , Eletromiografia , Polimiosite/complicações , Estudos RetrospectivosRESUMO
Apresentamos o caso de mulher com 57 anos de idade apresentando polimiosite, associada a infecçao pelo HTLV-I, sem manifestaçoes clínicas de acomentimento do sistema nervoso central e periférico. Fazemos alguns comentários sobre os aspectos fisiopatológicos do envolvimento muscular nas infecçoes pelo HTLV-I
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Infecções por HTLV-I/complicações , Polimiosite/virologia , Biópsia , Infecções por HTLV-I/patologia , Músculo Esquelético/patologia , Polimiosite/patologiaRESUMO
Primary biliary cirrhosis (PBC) is a cholestatic liver disease, which is characterized by a chronic inflammatory destruction of intrahepatic bile ducts. It is a rare disorder whose precise etiology is still to be elucidated. Even though the liver is the principal target of PBC, other organ systems also might be affected. Muscular involvement has rarely been described in this disease, and in the majority of cases, muscular weakness has been interpreted as polymyositis. We report the case of a 48-year-old woman suffering from classic PBC, in association with a myopathy whose histological features are distinct from the cases reported before. We also performed a MEDLINE research for PBC and concomitant muscular diseases
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Cirrose Hepática Biliar/complicações , Polimiosite/etiologia , Cirrose Hepática Biliar/diagnóstico , Cirrose Hepática Biliar/patologia , Polimiosite/patologiaRESUMO
Presentamos una paciente de sexo femenino de 42 años afectada de enfermedad de Charcot-Marie-Tooth. Hace dos años a nuestra paciente se le añade un cuadro de esclerodermia sistémica con insuficiencia pulmonar severa y síntomas típicamente dermatológicos. Los anticuerpos anti Scl 70 y anticentrómero fueron positivos. La anatomía patológica mostró además miositis y las características típicas de la esclerodermia. El tratamiento con corticoides, lidocaína y vasodilatadores periféricos no fue efectivo y nuestra paciente falleció
Assuntos
Humanos , Feminino , Adulto , Doença de Charcot-Marie-Tooth/complicações , Escleroderma Sistêmico/complicações , Polimiosite/complicações , Doença de Charcot-Marie-Tooth/imunologia , Doença de Charcot-Marie-Tooth/patologia , Escleroderma Sistêmico/patologia , Escleroderma Sistêmico/tratamento farmacológico , Polimiosite/patologiaRESUMO
We report a 68 years old male with a polymyositis associated to HTLV-I. Diagnosis was based on clinical picture, an increased creatin-phosphokinase levels, electromyography and muscle biopsy. The patient had positive HTVL-I antibodies, measured by particle agglutination test, indirect immunofluorescence and polymerase chain reaction in lymphocytes. Skin biopsy showed a mycosis fungoides. Schirmer test and minor salivary gland biopsy showed a dacryosialoadenitis. There was no central nervous system involvement. This patient is the only with positive HTLV-I antibodies, among 18 patients with polymiositis in whom these antibodies were measured
Assuntos
Humanos , Masculino , Idoso , Anticorpos Anti-HTLV-I/isolamento & purificação , Infecções por HTLV-I/complicações , Polimiosite/etiologia , Biópsia , Vírus Linfotrópico T Tipo 1 Humano/isolamento & purificação , Polimiosite/patologia , Creatina QuinaseRESUMO
En el presente trabajo se realiza una actualización sobre los hallazgos histopatológicos en la biopsia muscular de las miopatías inflamatorias idiopáticas, en función de los recientes conceptos de etiopatogenia de la dermatomiositis y polimiositis, tomando como punto de partida los casos diagnosticados en un período de 3 años y medio por nuestro equipo. Se destaca el valor de la biopsia muscular para confirmar la afectación muscular, excluir otras enfermedades neuromusculares y definir el diagnóstico de miopatía inflamatoria